Publications

Invitation to investigators

Publications arising from the BADBIR study will be written by "Banner authors" on behalf of the BADBIR "Study Group". The BADBIR Banner authors and Study Group will comprise authors who have:

  • 1) Made a relevant and substantial contribution to conception and design, aquisition of data, or analysis and interpretation of data;
  • 2) Drafted the article or revised it critically for important medical intellectual content;
  • 3) Provided final approval of the version to be published, in accordance with the Uniform Requirements for Manuscripts Submitted for Biomedical Journals.

We wish to recognise the important contributions made by investigators who are not part of the BADBIR Steering Committee. Investigators who have made important contributions to BADBIR, are willing to comply with the three conditions outlined above, and are keen to be involved are encouraged to apply. Applications will be reviewed by the BADBIR Research and Steering Committees. Applicants will then be informed of the committees' decision and relevant feedback will be provided if necessary.

Please send the completed application form to Dr Sagair Hussain, Biologics Manager, British Association of Dermatologists, 4 Fitzroy Square, London, W1T 5HQ. Alternatively the form can be sent by email: sagair@bad.org.uk. This must be sent by the date shown in the 'Deadline for applications' section of this page.

Publications

All of the publications based on BADBIR data are listed below. Each one has a link to PubMed where you can read the full details.

Click the links below to jump to the publication.


Design, Methodology and Objectives

Title: The British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR): Design, Methodology and Objectives.

Authors: A.D. Burden, R.B. Warren, C.E. Kleyn, K. McElhone, C.H. Smith, N.J. Reynolds, A.D. Ormerod, C.E.M. Griffiths, BADBIR Study Group.

British Journal of Dermatology, March 2012.

View on PubMed

Cost Effectiveness Analysis

Title: Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost-effectiveness analysis.

Authors: L.M. Sawyer, D. Wonderling, K. Jackson, R. Murphy, E.J. Samarasekera, C.H. Smith.

PharmacoEconomics, February 2015.

View on PubMed

Baseline Demographics

Title: Baseline characteristics of patients with psoriasis enrolled in the British Association of Dermatologists' Biologic and Immunomodulators Register.

Authors: I.Y.K Iskandar, Z.N. Yiu, R.B. Warren, K. McElhone, M. Lunt, A.D. Ormerod, N.J. Reynolds, C.H. Smith, C.E.M. Griffiths, D.M. Ashcroft.

British Journal of Dermatology, July 2015.

View on PubMed

Persistence with Biologic Therapies

Title: Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).

Authors: R.B. Warren, C.H. Smith, Z.Z.N. Yiu, D.M. Ashcroft, J.N.W.N. Barker, A.D. Burden, M. Lunt, K. McElhone, A.D. Ormerod, C.M.Owen, N.J. Reynolds, C.E.M. Griffiths.

Journal of Investigative Dermatology, June 2015.

View on PubMed

Factors on the Selection of First-Line Biologic Therapy

Title: Identification of factors that may influence the selection of first-line biologic therapy for people with psoriasis: a prospective, multi-centre cohort study.

Authors: N.J. Davison, R.B. Warren, K.J. Mason, K. McElhone, B. Kirby, A.D. Burden, C.H. Smith, K. Payne, C.E.M. Griffiths.

British Journal of Dermatology, April 2017.

View on PubMed

Patterns of Biologic Therapy Use

Title: Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).

Authors: I.Y.K. Iskandar, D.M. Ashcroft, R.B. Warren, I. Evans, K. McElhone, C.M. Owen, A.D. Burden, C.H. Smith, N.J. Reynolds, C.E.M. Griffiths.

British Journal of Dermatology, March 2017.

View on PubMed

Improvement in Quality of Life

Title: Comparative effectiveness of biologic therapies on improvements in quality of life in patients with psoriasis.

Authors: I.Y.K. Iskandar, D.M. Ashcroft, R.B. Warren, M. Lunt, K. McElhone, C.H. Smith, N.J. Reynolds, C.E.M. Griffiths.

British Journal of Dermatology, March 2017.

View on PubMed

Second-line persistence

Title: Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).

Authors: I.Y.K. Iskandar, R.B. Warren, M. Lunt, K.J. Mason, I. Evans, K. McElhone, C.H. Smith, N.J. Reynolds, D.M. Ashcroft, C.E.M. Griffiths.

Journal of Investigative Dermatology, December 2017

View on PubMed

Risk of serious infection

Title: Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).

Authors: Z.N. Yiu, C.H. Smith, D.M. Ashcroft, M. Lunt, S. Walton, R. Murphy, N.J. Reynolds, A.D. Ormerod, C.E.M. Griffiths, R.B. Warren.

Journal of Investigative Dermatology, October 2017.

View on PubMed

Adherence (iMAP)

Title: Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients' Medication Beliefs and Habit Strength.

Authors: R.J. Thorneloe, C.E.M. Griffiths, R. Emsley, D.M. Ashcroft, L. Cordingley.

Journal of Investigative Dermatology, November 2017

View on PubMed

Generating EQ-5D-3L Utility Scores from the DLQI

Title: Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis.

Authors: N.J. Davison, A.J. Thompson, A.J. Turner, L. Longworth, K. McElhone, C.E.M. Griffiths, K. Payne.

Value in Health, December 2017.

View on ScienceDirect

Safety and effectiveness profiles of patients eligible vs ineligible for clinical trials

Title: Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.

Authors: K.J. Mason, J.N.W.N. Barker, C.H. Smith, P.J. Hampton, M. Lunt, K. McElhone, R.B. Warren, Z.Z.N. Yiu, C.E.M. Griffiths, A.D. Burden.

JAMA Dermatology, March 2018.

View on PubMed

Risk of Cancer: Meta‐Analysis of Psonet Studies

Title: Cumulative exposure to biologics and risk of cancer in psoriasis patients: A meta‐analysis of Psonet studies from Israel, Italy, Spain, United Kingdom and Republic of Ireland.

Authors: I. Garcia‐Doval, M.A. Descalzo, K.J. Mason, A.D. Cohen, A.D. Ormerod, F.J. Gómez‐García, S. Cazzaniga, I. Feldhamer, H. Ali, E. Herrera‐Acosta, C.E.M. Griffiths, R. Stern, L. Naldi.

British Journal of Dermatology, May 2018.

View on PubMed

Abstracts


Baseline Demographics

Title: Baseline characteristics of patients with psoriasis enrolled in the British Association of Dermatologists' Biologic and Immunomodulators Register.

Authors: I.Y.K Iskandar, Z.N. Yiu, R.B. Warren, K. McElhone, M. Lunt, A.D. Ormerod, N.J. Reynolds, C.H. Smith, C.E.M. Griffiths, D.M. Ashcroft.

Presented at ESDR (poster), September 2014.


Persistence with Biologic Therapies

Title: Persistence with biologic therapies for the treatment of moderate-to-severe psoriasis: a prospective observational study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).

Authors: R.B. Warren, C.H. Smith, Z.Z.N. Yiu, D.M. Ashcroft, J.N.W.N. Barker, A.D. Burden, M. Lunt, K. McElhone, A.D. Ormerod, C.M.Owen, N.J. Reynolds, C.E.M. Griffiths.

Presented at BAD Gene To Clinic, December 2014.


Patterns of Biologic Drug Registration

Title: Patterns of Index Biologic Drug Registrations to a Pharmacovigilance Register of Psoriasis Patients.

Authors: K. Mason, I. Evans, K. McElhone, M. Lunt, S. Hussain, B. Kirby, D. Burden, N. Reynolds, C. Griffiths.

Presented at International Society for Pharmacoeconomics and Outcomes Research (ISPOR), November 2016.

Download abstract Download summary poster